DOP2024000233A - Conjugados anticuerpo-fármaco 5t4 y usos de los mismos - Google Patents
Conjugados anticuerpo-fármaco 5t4 y usos de los mismosInfo
- Publication number
- DOP2024000233A DOP2024000233A DO2024000233A DO2024000233A DOP2024000233A DO P2024000233 A DOP2024000233 A DO P2024000233A DO 2024000233 A DO2024000233 A DO 2024000233A DO 2024000233 A DO2024000233 A DO 2024000233A DO P2024000233 A DOP2024000233 A DO P2024000233A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- antibody
- drug conjugates
- present disclosure
- disclosure provides
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341957P | 2022-05-13 | 2022-05-13 | |
| PCT/US2023/066811 WO2023220620A2 (en) | 2022-05-13 | 2023-05-10 | 5t4 antibody-drug conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000233A true DOP2024000233A (es) | 2025-02-28 |
Family
ID=88731090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000233A DOP2024000233A (es) | 2022-05-13 | 2024-11-11 | Conjugados anticuerpo-fármaco 5t4 y usos de los mismos |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250060248A (ko) * | 2022-09-07 | 2025-05-07 | 엑셀리시스, 인코포레이티드 | 조직 인자 항체-약물 접합체 및 이의 용도 |
| KR20260114567A (ko) * | 2023-11-15 | 2026-07-22 | 엑셀리시스, 인코포레이티드 | 5t4 항체 약물 접합체 및 이의 사용 방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006010A (es) * | 2017-12-11 | 2020-10-16 | Triphase Res And Development Iii Corp | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. |
-
2023
- 2023-05-10 US US18/863,572 patent/US20250295803A1/en active Pending
- 2023-05-10 CR CR20240491A patent/CR20240491A/es unknown
- 2023-05-10 EP EP23804470.5A patent/EP4522157A2/en active Pending
- 2023-05-10 TW TW112117410A patent/TW202408585A/zh unknown
- 2023-05-10 IL IL316790A patent/IL316790A/en unknown
- 2023-05-10 KR KR1020247040730A patent/KR20250024875A/ko active Pending
- 2023-05-10 CN CN202380052757.2A patent/CN119522097A/zh active Pending
- 2023-05-10 CN CN202510757191.4A patent/CN120571033A/zh active Pending
- 2023-05-10 AU AU2023268538A patent/AU2023268538A1/en active Pending
- 2023-05-10 CA CA3252237A patent/CA3252237A1/en active Pending
- 2023-05-10 PE PE2024002516A patent/PE20251184A1/es unknown
- 2023-05-10 WO PCT/US2023/066811 patent/WO2023220620A2/en not_active Ceased
- 2023-05-10 JP JP2024566281A patent/JP2025516569A/ja active Pending
-
2024
- 2024-11-08 MX MX2024013869A patent/MX2024013869A/es unknown
- 2024-11-11 DO DO2024000233A patent/DOP2024000233A/es unknown
- 2024-11-11 CL CL2024003441A patent/CL2024003441A1/es unknown
- 2024-11-12 CO CONC2024/0015381A patent/CO2024015381A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202408585A (zh) | 2024-03-01 |
| PE20251184A1 (es) | 2025-04-23 |
| US20250295803A1 (en) | 2025-09-25 |
| WO2023220620A3 (en) | 2023-12-14 |
| CA3252237A1 (en) | 2023-11-16 |
| CR20240491A (es) | 2025-01-07 |
| KR20250024875A (ko) | 2025-02-19 |
| CO2024015381A2 (es) | 2025-02-24 |
| CN120571033A (zh) | 2025-09-02 |
| WO2023220620A2 (en) | 2023-11-16 |
| CN119522097A (zh) | 2025-02-25 |
| CL2024003441A1 (es) | 2025-02-28 |
| MX2024013869A (es) | 2024-12-06 |
| IL316790A (en) | 2025-01-01 |
| JP2025516569A (ja) | 2025-05-30 |
| EP4522157A2 (en) | 2025-03-19 |
| AU2023268538A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024015381A2 (es) | Conjugados anticuerpo-fármaco 5t4 y usos de los mismos | |
| CO2025013047A2 (es) | Conjugados de anticuerpo dll3-fármaco y usos de estos | |
| CO2021015184A2 (es) | Conjugados de anticuerpo y fármaco | |
| MX2019005879A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
| MX2024014176A (es) | Compuestos aza-tetraciclicos de oxazepina y usos de los mismos | |
| CO2020010303A2 (es) | Conjugados de il-15, y sus usos | |
| EP4117729A4 (en) | ANTIBODY DRUG CONJUGATE | |
| BR112023014128A2 (pt) | Conjugados de anticorpo-fármaco imunomodulatórios | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| DOP2020000119A (es) | Conjugados anticuerpo anti-cd40-fármaco | |
| MX2020003125A (es) | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. | |
| CO2018004152A2 (es) | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso | |
| CO2023012821A2 (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
| CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CO2022003742A2 (es) | Conjugados de interleuquina 10 y sus usos | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| UY37669A (es) | Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos | |
| ECSP23042551A (es) | Conjugados de anticuerpo y fármaco | |
| MX2023009146A (es) | Anticuerpos y usos de estos. | |
| MX2023012848A (es) | Conjugados de anticuerpo-farmaco anti-c-met. | |
| CL2020003044A1 (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| CO2024015383A2 (es) | Agentes aglutinantes 5t4 y usos de los mismos | |
| EP4240425A4 (en) | Ocular antibody-drug conjugates | |
| CA3242972A1 (en) | Anti-ROR1 antibodies, anti-ROR1 antibody-drug combinations, and their medical uses | |
| MX2024002407A (es) | Anticuerpos y conjugados sirp-alfa. |